Kathryn Neupert
Pediatric Allergy/Immunology · Baton Rouge, LANPI 1336535525
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,037, more than ten times the $108 reported in 2019.
Across 433 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$986
- GSK$860
- Regeneron Healthcare Solutions, Inc.$816
- Genentech USA, Inc.$715
- CSL Behring$678
- Novartis$542
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,73599%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $986 |
| GSK | 56 | $860 |
| Regeneron Healthcare Solutions, Inc. | 37 | $816 |
| Genentech USA, Inc. | 30 | $715 |
| CSL Behring | 33 | $678 |
| Novartis | 32 | $542 |
| Pfizer | 26 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $488 |
| Grifols USA, LLC | 19 | $413 |
| Amgen(2 entities) | 23 | $328 |
| Sanofi | 14 | $285 |
| Incyte Corporation | 8 | $187 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $179 |
| Biocryst US Sales Co., LLC | 6 | $176 |
| Baxter Healthcare | 5 | $145 |
| Galderma Laboratories, L.p. | 9 | $139 |
| Optinose US, Inc. | 7 | $136 |
| Lilly USA, LLC | 5 | $133 |
| Octapharma USA, Inc. | 1 | $126 |
| Organon | 5 | $124 |
| Alk-abello, Inc | 6 | $117 |
| Advanced Respiratory, Inc | 5 | $114 |
| Kaleo, Inc. | 7 | $108 |
| LEO Pharma Inc. | 6 | $91 |
| Shire North American Group Inc | 4 | $73 |
| Pharming Healthcare, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Arcutis Biotherapeutics, Inc. | 2 | $40 |
| ADMA Biomanufacturing LLC | 2 | $38 |
| Biocryst Pharmaceuticals, Inc. | 2 | $31 |
| Aytu Biopharma, Inc. | 2 | $29 |
| GC Biopharma USA, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric allergy/immunology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $80,282 |
| XolairOmalizumab | 12 | $33,612 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,432 |
| Levocetirizine Dihydrochloride | 48 | $648 |
| Fluticasone Propionate | 25 | $343 |
| Azelastine Hcl | 11 | $265 |
| Ipratropium Bromide | 11 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $860 | $8,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other pediatric allergy/immunology in Baton Rouge
- Theron McCormickBaton Rouge$52K
- Sandhya ManiBaton Rouge$31K
- Benjamin CloseAlexandria$421K
- Ricardo SorensenNew Orleans$37K
- Sami BahnaShreveport$11K
- Andrew AbreoNew Orleans$7K
- Adil KhanShreveport$6K
- Jane Sayem El-DahrNew Orleans$1K
- Nina HeinNew Orleans$458
- Augusto OchoaNew Orleans$50
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.